FRBK stock was delisted from NASDAQ on
Aug 22, 2023. You can explore more stocks from
Financial Services sector on this page.
ZVRA Zevra Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: ZVRA
Price (delayed)
$12.02
Market cap
$657.25M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.92
Enterprise value
$681.75M
KemPharm is a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs to treat serious medical conditions through its proprietary LAT™ (Ligand Activated Therapy) technology. KemPharm utilizes
Highlights
ZVRA's gross profit has soared by 98% from the previous quarter and by 26% YoY
ZVRA's revenue has soared by 72% QoQ and by 46% YoY
Zevra Therapeutics's net income has shrunk by 86% YoY but it has increased by 13% QoQ
Zevra Therapeutics's EPS has decreased by 45% YoY but it has increased by 16% QoQ
ZVRA's debt is up by 40% year-on-year and by 2.6% since the previous quarter
Key stats
What are the main financial stats of ZVRA
Market
Valuations
Earnings
Shares outstanding
54.68M
Market cap
$657.25M
Enterprise value
$681.75M
Price to earnings (P/E)
N/A
Price to book (P/B)
15.86
Price to sales (P/S)
16.02
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
16.8
Revenue
$40.59M
Gross profit
$32M
Operating income
-$71.88M
Net income
-$91.99M
EBIT
-$66.78M
EBITDA
-$60.3M
Free cash flow
-$61.82M
Per share
Balance sheet
Liquidity
EPS
-$1.92
EPS diluted
-$1.92
Free cash flow per share
-$1.14
Book value per share
$0.76
Revenue per share
$0.75
TBVPS
$1.86
Total assets
$172.71M
Total liabilities
$131.69M
Debt
$61.84M
Equity
$41.02M
Working capital
$54.6M
Debt to equity
1.51
Current ratio
3.02
Quick ratio
2.79
Net debt/EBITDA
-0.41
Margins
Efficiency
Dividend
EBITDA margin
-148.6%
Gross margin
78.8%
Net margin
-226.6%
Operating margin
-177.1%
Return on assets
-53.6%
Return on equity
-201.1%
Return on invested capital
-77.2%
Return on capital employed
-45.8%
Return on sales
-164.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ZVRA stock price
How has the Zevra Therapeutics stock price performed over time
Intraday
3.98%
1 week
23.41%
1 month
29.53%
1 year
113.88%
YTD
44.12%
QTD
36.44%
Financial performance
How have Zevra Therapeutics's revenue and profit performed over time
Revenue
$40.59M
Gross profit
$32M
Operating income
-$71.88M
Net income
-$91.99M
Gross margin
78.8%
Net margin
-226.6%
ZVRA's gross profit has soared by 98% from the previous quarter and by 26% YoY
Zevra Therapeutics's net income has shrunk by 86% YoY but it has increased by 13% QoQ
ZVRA's revenue has soared by 72% QoQ and by 46% YoY
The operating margin has soared by 52% from the previous quarter and by 14% YoY
Price vs fundamentals
How does ZVRA's price correlate with its fundamentals
Growth
What is Zevra Therapeutics's growth rate over time
Valuation
What is Zevra Therapeutics stock price valuation
P/E
N/A
P/B
15.86
P/S
16.02
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
16.8
Zevra Therapeutics's EPS has decreased by 45% YoY but it has increased by 16% QoQ
The price to book (P/B) is 93% higher than the last 4 quarters average of 8.2
Zevra Therapeutics's equity has decreased by 16% YoY but it has increased by 3.4% from the previous quarter
ZVRA's revenue has soared by 72% QoQ and by 46% YoY
ZVRA's P/S is 42% above its 5-year quarterly average of 11.3 and 32% above its last 4 quarters average of 12.1
Efficiency
How efficient is Zevra Therapeutics business performance
ZVRA's ROE has shrunk by 151% YoY but it is up by 9% QoQ
The company's return on assets has shrunk by 54% YoY but it rose by 15% QoQ
Zevra Therapeutics's return on sales has surged by 53% QoQ and by 3.7% YoY
Zevra Therapeutics's return on invested capital has increased by 30% QoQ and by 7% YoY
Dividends
What is ZVRA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ZVRA.
Financial health
How did Zevra Therapeutics financials performed over time
The total assets is 31% greater than the total liabilities
The company's current ratio rose by 44% YoY and by 19% QoQ
The quick ratio has increased by 37% year-on-year and by 19% since the previous quarter
ZVRA's debt is 51% greater than its equity
The debt to equity has soared by 66% YoY
ZVRA's debt is up by 40% year-on-year and by 2.6% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.